Danish drugmaker Novo Nordisk said several hundred counterfeit units of its diabetes drug Ozempic were being distributed in ...

Novo Nordisk is set to benefit from a $150B market by 2030, with strong earnings potential and a favorable 14x forward P/E.

Danish drugmaker Novo Nordisk said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being ...

The FDA has issued a warning about counterfeit Ozempic medications, sharing the lot numbers and serial numbers of products ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

The maker of Ozempic and the weight loss drug Wegovy told the FDA on April 3 that counterfeit 1-milligram injections were ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...